Key Takeaways
- • Sofinnova Partners closed Crossover II, its largest fund ever, at 725 million euros (about $815 million), according to a Monday release.
- • The fund lifts the total value of Sofinnova's investment umbrella to more than 5 billion euros (around $5.5 billion).
- • Crossover II plans to invest in around 15 clinical-stage companies, with about 80% of capital directed to Europe.
- • The strategy prioritizes follow-on investment and longer ownership stakes, with partner Kinam Hong saying the firm "cannot be passive investors."
- • Predecessor Crossover I backed companies later acquired for hundreds of millions to over $1 billion, including Calliditas Therapeutics and Amolyt Pharma.
Summary
Sofinnova partner Kinam Hong, M.D., told Fierce that the fund is focused on immunology, inflammation, oncology, central nervous system disorders, rare disease and cardiometabolic disease. Hong said the firm is seeking companies with the potential to become global leaders rather than assets simply suited for sale. Among the first investments are Ireland's Neurent Medical, which is developing a treatment device for chronic rhinitis; Denmark's Hemab Therapeutics, focused on bleeding and clotting disorder therapies; and the U.K.'s CellCentric, which is developing an oral oncology platform. Hong said about 80% of the fund will be invested in Europe.
The predecessor fund, Crossover I, backed companies that have since been acquired or gone public. These include LimFlow, bought by Inari Medical for $415 million in 2023; Calliditas Therapeutics, acquired by Asahi Kasei for more than $1 billion in 2024; and Amolyt Pharma, which AstraZeneca acquired for $800 million the same year. Abivax, which received a $14 million Sofinnova investment in 2019 under Crossover I, completed a successful IPO in 2023 under CEO Marc de Garidel, whom Hong credited with an important role in the company's transition.
A key distinction of Crossover II is its emphasis on follow-on investment, which Hong said allows the firm to support companies longer and maintain meaningful ownership through key milestones. He stressed that the firm works closely with management teams and does not build companies around a single exit route, while acknowledging that biotech failures can occur when the science does not work. Hong argued Europe has strong science but lacks large specialist pools of later-stage capital, a gap the fund is designed to address. He added that pharma faces significant patent expiries through 2030 and beyond, and that Europe is well placed to supply new products.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.